Hologic’s Cynosure division expands its body contouring portfolio with the launch of two new products: the TempSure Firm handpiece and a petite mask for SculpSure submental treatments.
SculpSure submental treatments are now FDA-cleared for patients with a body mass index (BMI) up to 49 — reportedly the highest BMI clearance on the market for submental treatments.
The TempSure Firm handpiece is designed to deliver monopolar radiofrequency energy through massage heads to gently heat tissue and temporarily reduce the appearance of cellulite. The new 60-mm handpiece allows practitioners to treat larger areas of the body at a faster rate, without surgery or downtime.
Cynosure also received 510(k) clearance from the FDA for its petite submental mask, which attaches to the SculpSure platform. This new product will allow practitioners to perform WarmSculpting Profile treatments of submental fat (known as “double chin”) on patients with a narrow jawline, per a media release from Cynosure.
“The WarmSculpting Profile treatment was already a game changer for addressing the double chin, and after listening to customer feedback, we are excited to introduce the petite mask — the latest evolution of the cutting-edge SculpSure device,” says Erik Anderson, Hologic’s Division President, Cynosure, in the release.
“Our clinicians tell us almost 20 percent of their patients have smaller, narrow jawlines, and with the new petite mask, they can help even more men and women feel their best with non-surgical fat reduction in that area. The updated BMI clearance of 49 for all submental treatments is a clear competitive advantage and underscores our market-leader status in the body contouring category.”
“The TempSure Firm handpiece enhances the functionality and versatility of our already cutting-edge TempSure radiofrequency platform,” Anderson adds. “The larger 60-mm handpiece allows practitioners to further expand and differentiate their practices, while treating more patients seeking to temporarily reduce the appearance of cellulite. These launches are prime examples of the continuous innovation we are committed to in order to best serve our patients and providers.”
In conjunction with these launches, Cynosure has updated its SculpSure software to include a new, optional, guided mode feature. Developed to help clinicians treat patients more easily, it features a preset algorithm for energy titration, resulting in a controlled increase in temperature to achieve lipolysis, as well as energy setting parameters designed to guide providers into a repeatable and comfortable treatment for their patients, the release continues.